We are live on
!
Find out more
ABI
Adamant Biomedical Investments Portfolio holdings
AUM
$418M
This Fund
S&P 500
This Quarter
Est. Return
+10.95%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$418M
AUM Growth
+$17.7M
(+4.4%)
Cap. Flow
-$20M
Cap. Flow
% of AUM
-4.77%
Top 10 Holdings %
Top 10 Hldgs %
32.81%
Holding
108
New
12
Increased
10
Reduced
35
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
HSP
HOSPIRA INC
HSP
|
+$5.08M |
| 2 |
WX
WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS
WX
|
+$4.94M |
| 3 |
Acadia Pharmaceuticals
ACAD
|
+$4.82M |
| 4 |
MDVN
MEDIVATION, INC.
MDVN
|
+$4.68M |
| 5 |
Ligand Pharmaceuticals
LGND
|
+$4.24M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
|
+$4.8M |
| 2 |
ProShares Ultra NASDAQ Biotechnology
BIB
|
+$4.11M |
| 3 |
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
|
+$4.02M |
| 4 |
Teva Pharmaceuticals
TEVA
|
+$3.9M |
| 5 |
QGENF
QIAGEN NV
QGENF
|
+$3.53M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 87.28% |
| 2 | Financials | 0.93% |
| 3 | Industrials | 0.35% |
| 4 | Technology | 0.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Centene
CNC
$32.5B
| $5.36M | 1.28% |
206,440
-107,400
| -34% | -$2.51M |
|
|
SLXP
27
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
| $5.17M | 1.24% |
45,000
-33,210
| -42% | -$4.02M |
|
28
Cigna
CI
$74.6B
| $5.15M | 1.23% |
50,000
| – | – |
|
29
Incyte
INCY
$24.4B
| $5.12M | 1.22% |
70,000
| – | – |
|
30
Molina Healthcare
MOH
$10.3B
| $4.91M | 1.17% |
91,710
-39,340
| -30% | -$1.91M |
|
|
ESRX
31
DELISTED
Express Scripts Holding Company
ESRX
| $4.83M | 1.15% |
57,000
| – | – |
|
32
Baxter International
BAX
$14.2B
| $4.76M | 1.14% |
119,665
| – | – |
|
33
Brookdale Senior Living
BKD
$3.4B
| $4.75M | 1.14% |
129,540
-8,080
| -6% | -$274K |
|
|
WX
34
DELISTED
WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS
WX
| $4.71M | 1.13% |
+140,000
| New | +$4.94M |
|
|
35
Ligand Pharmaceuticals
LGND
$6.36B
| $4.33M | 1.03% |
+130,292
| New | +$4.24M |
|
36
Humana
HUM
$46.2B
| $4.31M | 1.03% |
30,000
-5,000
| -14% | -$683K |
|
37
Johnson & Johnson
JNJ
$625B
| $4.18M | 1% |
40,000
-5,000
| -11% | -$527K |
|
|
LCI
38
DELISTED
Lannett Company, Inc.
LCI
| $4.04M | 0.97% |
23,553
+3,553
| +18% | +$659K |
|
39
HCA Healthcare
HCA
$89.5B
| $4.04M | 0.96% |
55,000
+10,000
| +22% | +$703K |
|
40
AbbVie
ABBV
$435B
| $3.93M | 0.94% |
+60,000
| New | +$3.78M |
|
41
Stryker
SYK
$130B
| $3.92M | 0.94% |
41,500
-16,000
| -28% | -$1.42M |
|
|
AET
42
DELISTED
Aetna Inc
AET
| $3.91M | 0.93% |
44,000
-16,000
| -27% | -$1.34M |
|
43
Elevance Health
ELV
$85.5B
| $3.77M | 0.9% |
30,000
-8,000
| -21% | -$989K |
|
44
Bristol-Myers Squibb
BMY
$132B
| $3.54M | 0.85% |
60,000
+10,000
| +20% | +$564K |
|
45
Perrigo
PRGO
$1.78B
| $3.33M | 0.8% |
20,000
-10,750
| -35% | -$1.68M |
|
|
STJ
46
DELISTED
St Jude Medical
STJ
| $3.32M | 0.79% |
51,000
-14,000
| -22% | -$902K |
|
47
Jazz Pharmaceuticals
JAZZ
$16.7B
| $3.27M | 0.78% |
20,000
| – | – |
|
48
BioMarin Pharmaceuticals
BMRN
$12.4B
| $3.25M | 0.78% |
36,000
-14,000
| -28% | -$1.16M |
|
49
CVS Health
CVS
$122B
| $2.89M | 0.69% |
30,000
-15,000
| -33% | -$1.32M |
|
|
ENDP
50
DELISTED
Endo International plc
ENDP
| $2.88M | 0.69% |
40,000
| – | – |
|
Similar funds
AGCJ
ACM
RNS
NTP
MMC
LOM
CAMI
NES
Adamant Biomedical Investments's Q4 2014 Portfolio in Review
As of Q4 2014, Adamant Biomedical Investments held 108 positions worth $418M, up 4.4% from $401M the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Adamant Biomedical Investments withdrew a net $20M in Q4 2014, closing 7 positions and reducing 35 holdings. Its most notable exit was Insulet, an estimated $2.95M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 87% a quarter earlier, followed by Financials and Industrials.
Against the trend, Adamant Biomedical Investments opened a new position in HOSPIRA INC worth $5.51M.
- Adamant Biomedical Investments's largest Q4 2014 buy was HOSPIRA INC: 90,000 shares worth $5.51M.
- Adamant Biomedical Investments added most to Acadia Pharmaceuticals in Q4 2014, an estimated $4.82M increase.
- Adamant Biomedical Investments's biggest Q4 2014 reduction was COVIDIEN PLC COM SHS NEW (IRELAND), cutting an estimated $4.8M.
- Adamant Biomedical Investments fully exited Insulet in Q4 2014, selling an estimated $2.95M.
- Adamant Biomedical Investments's ten largest holdings make up 33% of its $418M portfolio in Q4 2014.
- Adamant Biomedical Investments opened 12 new positions and closed 7 in Q4 2014.
- Adamant Biomedical Investments's portfolio value rose 4.4% quarter-over-quarter to $418M.
Based on Adamant Biomedical Investments's 13F filing for Q4 2014, filed 13 Feb 2015.